Innovent Biologics Inc - ESG Rating & Company Profile powered by AI
Full Sustainability assessment of Innovent Biologics Inc can be reached by logging in. The article includes a Q&A table for Innovent Biologics Inc. If you work at Innovent Biologics Inc and you would like to use your Sustainability aseessment, please contact us.
Innovent Biologics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.1; made up of an environmental score of 3.0, social score of 1.0 and governance score of 2.3.
2.1
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1551 | Voyager Life PLC | 2.2 | Medium |
1551 | Source Natural Foods and Herbal Supplements Ltd | 2.2 | Medium |
1571 | Innovent Biologics Inc | 2.1 | Medium |
1571 | Cerevel Therapeutics Holdings Inc | 2.1 | Medium |
1571 | Charlotte's Web Holdings Inc | 2.1 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Innovent Biologics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Innovent Biologics Inc disclose current and historical energy intensity?
Does Innovent Biologics Inc report the average age of the workforce?
Does Innovent Biologics Inc reference operational or capital allocation in relation to climate change?
Does Innovent Biologics Inc disclose its ethnicity pay gap?
Does Innovent Biologics Inc disclose cybersecurity risks?
Does Innovent Biologics Inc offer flexible work?
Does Innovent Biologics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Innovent Biologics Inc disclose the number of employees in R&D functions?
Does Innovent Biologics Inc conduct supply chain audits?
Does Innovent Biologics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Innovent Biologics Inc conduct 360 degree staff reviews?
Does Innovent Biologics Inc disclose the individual responsible for D&I?
Does Innovent Biologics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Innovent Biologics Inc disclose current and / or historical scope 2 emissions?
Does Innovent Biologics Inc disclose water use targets?
Does Innovent Biologics Inc have careers partnerships with academic institutions?
Did Innovent Biologics Inc have a product recall in the last two years?
Does Innovent Biologics Inc disclose incidents of discrimination?
Does Innovent Biologics Inc allow for Work Councils/Collective Agreements to be formed?
Has Innovent Biologics Inc issued a profit warning in the past 24 months?
Does Innovent Biologics Inc disclose parental leave metrics?
Does Innovent Biologics Inc disclose climate scenario or pathway analysis?
Does Innovent Biologics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Innovent Biologics Inc disclose the pay ratio of women to men?
Does Innovent Biologics Inc support suppliers with sustainability related research and development?
Does Innovent Biologics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Innovent Biologics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Innovent Biologics Inc involved in embryonic stem cell research?
Does Innovent Biologics Inc disclose GHG and Air Emissions intensity?
Does Innovent Biologics Inc disclose its waste policy?
Does Innovent Biologics Inc report according to TCFD requirements?
Does Innovent Biologics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Innovent Biologics Inc disclose energy use targets?
Does Innovent Biologics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Innovent Biologics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Innovent Biologics Inc
These potential risks are based on the size, segment and geographies of the company.
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.